MetaPhore Pharmaceuticals has received US Food and Drug Administrationapproval of its Investigational New Drug application to conduct Phase I clinical trials to determine the pharmacokinetics of M40403 for the treatment of advanced skin and end-stage kidney cancers. The company will then conduct Phase II trials which will evaluate M40403 as a co-therapy with interleukin-2, as it has previously been shown to significantly improve the effectiveness of the latter in preclinical studies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze